On this episode of Growth Stories, we take a look at the escalating rivalry between Novo Nordisk and Eli Lilly and how the Danish drugmaker lost its grip on the weight-loss drug market. 
 Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices">megaphone.fm/adchoices</a>

On this episode of Growth Stories, we take a look at the escalating rivalry between Novo Nordisk and Eli Lilly and how the Danish drugmaker lost its grip on the weight-loss drug market. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of Growth Stories, we take a look at the escalating rivalry between Novo Nordisk and Eli Lilly and how the Danish drugmaker lost its grip on the weight-loss drug market.&nbsp;
 Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="noopener noreferrer">megaphone.fm/adchoices</a>

Novo Nordisk Is Losing Its Lead To Eli Lilly In The Obesity Drug War. Here’s What Went Wrong.

Growth Stories is a podcast about the innovations and trends driving the stock market’s next big winners. IBD multimedia reporter Alexis Garcia interviews analysts, executives, authors and influencers to take investors behind the latest innovations and trends driving growth in leading companies and sectors.

Share Novo Nordisk Is Losing Its Lead To Eli Lilly In The Obesity Drug War. Here’s What Went Wrong.

Sign up to save your podcasts

Novo Nordisk Is Losing Its Lead To Eli Lilly In The Obesity Drug War. Here’s What Went Wrong.

Novo Nordisk Is Losing Its Lead To Eli Lilly In The Obesity Drug War. Here’s What Went Wrong.

More shows like Growth Stories With IBD

Investing With IBD

The Zero100 Podcast